Genmab AS

Genmab AS Stock-Based Compensation

The Stock-Based Compensation (SBC) of Genmab AS (GMAB) as of Oct 18, 2026 is 128.00 M USD. In the previous year, Stock-Based Compensation (SBC) was 721.00 M USD — a change of -82.25% (lower).

Stock-Based Compensation

128.00 MUSD

YoY

-82.25%

Last updated:

Stock-Based Compensation (SBC) of Genmab AS is 2025 128.00 M USD. Stock-Based Compensation (SBC) of Genmab AS was 2024 721.00 M USD. It decreases by -82.25% lower compared to the previous year.

The Genmab AS Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2018
90.76 M USD
Jan 1, 2019
147.00 M USD
Jan 1, 2020
200.00 M USD
Jan 1, 2021
310.00 M USD
Jan 1, 2022
439.00 M USD
Jan 1, 2023
586.00 M USD
Jan 1, 2024
721.00 M USD
Jan 1, 2025
128.00 M USD
The Genmab AS Stock-Based Compensation history
YEARStock-Based CompensationYoY
128.00 MUSD-82.25%
721.00 MUSD+23.04%
586.00 MUSD+33.49%
439.00 MUSD+41.61%
310.00 MUSD+55.00%
200.00 MUSD+36.05%
147.00 MUSD+61.97%
90.76 MUSD+19.44%
75.99 MUSD+42.86%
53.19 MUSD+45.47%
36.56 MUSD+31.91%
27.72 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genmab AS Stock analysis

What does Genmab AS do? Genmab AS is a biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. It develops and markets antibody-based therapies for cancer and other diseases, including EPKINLY, TEPKINLY, and Tivdak for various lymphomas and cervical cancer. The company also advances several product candidates in clinical development, such as Epcoritamab for lymphomas and GEN1059 for solid tumors, alongside established treatments like DARZALEX and TECVAYLI for multiple myeloma and other conditions. Genmab AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab AS stock

Stock-Based Compensation (SBC) of Genmab AS is 128.00 M USD in 2025.

Stock-Based Compensation (SBC) of Genmab AS changed from 721.00 M USD to 128.00 M USD, representing a -82.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Genmab AS since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Genmab AS historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Genmab AS

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Genmab AS